{
  "id": 16792519,
  "title": "Novel HDAC Inhibitor Hits Main Goal in Unresectable Melanoma Trial",
  "url": "https://urgent.news/2026/10/27/novel-hdac-inhibitor-hits-main-goal-in-unresectable-melanoma-trial",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-27T19:34:36.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/esmo/123607"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- Progression-free survival (PFS) in unresectable melanoma improved significantly with the addition of an investigational histone deacetylase (HDAC) inhibitor to immunotherapy, a randomized trial showed. Median PFS increased from...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}